Yonhap News AgencyDecember 9, 2013 02:49
SEOUL, Dec. 9 (Yonhap) -- LG Life Sciences Ltd., one of South Korea's leading pharmaceutical companies, said Monday that it has signed a deal with the Mexican drug firm Stendhal to provide its new diabetes medicine.
Stendhal will sell the LG Life's "Zemiglo" and "ZemiMet" to 23 countries in Central and South America such as Mexico, Venezuela and Colombia, the South Korean company said, adding it expects to earn up to US$25 million.
LG Life now has a sales network for its diabetes drugs in 104 countries.
<All rights reserved by Yonhap News Agency>